ReviewPharmaceutics2021
Gastroretentive Technologies in Tandem with Controlled-Release Strategies: A Potent Answer to Oral Drug Bioavailability and Patient Compliance Implications.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Formulation and optimization of gastroretentive tablets containing famotidine in combination with antacids: In vitro evaluations and stability studies.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Article
- Article
- Formulation approaches for colon-specific drug delivery: conventional to nanocarrier systems.RSC advances · 2026Review
- Quality by design approach for optimization, in-vitro and in-vivo evaluation of compression-spheronized itopride hydrochloride loaded gastroretentive pellets for the treatment of gastroesophageal reflux disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- HPMC Substitution Influences the Buoyancy and Release in Gastroretentive Floating Tablets.AAPS PharmSciTech · 2026Article
- Design and evaluation of a novel expandable gastroretentive film for sustained Metoprolol release.PloS one · 2026Article
- Advancing Drug Stability Using Non-Aqueous Gels: Properties, Applications, and Emerging Challenges.Recent advances in drug delivery and formulation · 2026Review
- Advancements and Challenges in Gastroretentive Drug Delivery Systems: A Comprehensive Review of Research Innovation, Technologies, and Clinical Applications.Recent advances in drug delivery and formulation · 2026Review
- Link between physical activity, nutrition, and antimicrobial pharmacokinetics and therapeutic efficacy: Implications for resistance management.SAGE open medicine · 2026Review
- Bioavailability Enhancement of Curcumin by PEG-Based Gastroretentive System: Development and In Vitro Evaluation.Pharmaceutics · 2025Article
- Expandable Gastroretentive Films Based on Anthocyanin-Rich Rice Starch for Improved Ferulic Acid Delivery.Polymers · 2025Article
- Dual-Mechanism Gastroretentive Tablets with Encapsulated Gentian Root Extract.Pharmaceutics · 2025Article
- Development of Novel Oral Delivery Systems Using Additive Manufacturing Technologies to Overcome Biopharmaceutical Challenges for Future Targeted Drug Delivery.Pharmaceutics · 2024Article
- Improving the Anti-Tumor Effect of Indoleamine 2,3-Dioxygenase Inhibitor CY1-4 by CY1-4 Nano-Skeleton Drug Delivery System.Journal of functional biomaterials · 2024Article
- Strap-on Buoyant Device to Enhance Gastrointestinal Tract Retention of Felodipine Osmotic Pump Tablets.AAPS PharmSciTech · 2024Article
- Development and Evaluation of a Cost-Effective, Carbon-Based, Extended-Release Febuxostat Tablet.Molecules (Basel, Switzerland) · 2024Article
- Gastroretentive Delivery Approach to Address pH-Dependent Degradation of (+)- and (-)-Phenserine.AAPS PharmSciTech · 2024Article
- Modeling and evaluation of ivermectin release kinetics from 3D-printed tablets.Therapeutic delivery · 2024Article
- Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.Drug delivery · 2023Article
- Bilosomes and Biloparticles for the Delivery of Lipophilic Drugs: A Preliminary Study.Antioxidants (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
There have been many efforts to improve oral drug bioavailability and therapeutic efficacy and patient compliance. A variety of controlled-release oral delivery systems have been developed to meet these needs. Gastroretentive drug delivery technologies have the potential to achieve retention of the dosage form in the upper gastrointestinal tract (GIT) that can be sufficient to ensure complete solubilisation of the drugs in the stomach fluids, followed by subsequent absorption in the stomach or proximal small intestine. This can be beneficial for drugs that have an "absorption window" or are absorbed to a different extent in various segments of the GIT. Therefore, gastroretentive technologies in tandem with controlled-release strategies could enhance both the therapeutic efficacy of many drugs and improve patient compliance through a reduction in dosing frequency. The paper reviews different gastroretentive drug delivery technologies and controlled-release strategies that can be combined and summarises examples of formulations currently in clinical development and commercially available gastroretentive controlled-release products. The different parameters that need to be considered and monitored during formulation development for these pharmaceutical applications are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.